Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
efineptakin alfa + bevacizumab
- Development stage
- Unknown
- Lead developer
- NeoImmuneTech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Intramuscular
01
Overview
**Efineptakin alfa + bevacizumab** is an experimental combination therapy under clinical investigation, particularly for recurrent glioblastoma. Efineptakin alfa (also known as GX-I7 or NT-I7) is a long-acting recombinant human interleukin-7 (IL-7) designed to increase T cell numbers, thereby enhancing antitumor immune responses. Bevacizumab is a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), thereby inhibiting angiogenesis and tumor blood vessel formation. The combination is being tested to leverage both immune stimulation (by IL-7) and anti-angiogenic (by VEGF blockade) activity, with the goal of improving outcomes in highly aggressive tumors such as glioblastoma[3][5].
- Brand names
- Avastin + efineptakin alfa
- Other names
- efineptakin alfa + bevacizumab
02
Targets
IL7R (Interleukin-7 Receptor)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on efineptakin alfa + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on efineptakin alfa + bevacizumab.